Big Pharma

Clinical testing of drugs on dogs is a cruel practice, doesn't add value or provide data that is applicable to humans

The primary objection to the specific use of dogs in testing is thus simple — the data derived from dogs is not predictive enough to be applied to the case of humans

Why Narendra Modi’s US visits make the sick and poor in India anxious

The fear is that if Narendra Modi capitulates to US pressure on India’s Intellectual Property Rights (IPR) regime, which it has been overtly and covertly exerting for years, it will make many lifesaving drugs unaffordable

Breast cancer drugs: Is UPA succumbing to US pharma pressure?

There has been a systematic effort by the western media, international business bodies and their trade proxies to malign India. Perhaps the biggest pressure came from the US, both by the government and trade and business organisations. <br /><br />

India revokes GSK patent on breast cancer drug Tykerb

India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.

How Big Pharma-designed cacophony against Ranbaxy drowns vital voices

In the unresisted and rapidly rising cacophony against the FDA-tainted Ranbaxy, what get drowned unfortunately are voices that are vital to the country's drug industry and people's health.

Ranbaxy debacle: Big Pharma's target is Indian drug industry

It's abundantly clear that the Ranbaxy fiasco in the US, in which the company has to pay $500 million for allegedly selling adulterated drugs, is the big opportunity that the multinational drug companies have been waiting for to malign India.

HC denies interim relief to Merck in patent case against Glenmark

The interim application of the multinational pharma major that Glenmark be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature was denied by the court.<br /><br />

Novartis patent blow: Why Big Pharma can't quit India

Much of the new business will still come from cheap generics made by local companies, but Western firms are also seeking to put their brands on unpatented medicines, prompting the likes of Abbott Laboratories and Daiichi Sankyo to buy up Indian companies.

Novartis judgment: Let's make research a priority, rest will follow

Our academic and research institutions have to make research a priority and the government has to liberally fund them. The bottomline of the Glivec and recent experiences is simple - we should get our priorities right. The rest will fall in place. <br /><br />

Drug R&D: Why India can easily ignore Novartis blackmail

India is a country where pharma companies can do research and development at lower cost. Ignoring this fact will be detrimental for the Big Pharma.